

AGREEMENT WITH PATIENT ASSOCIATION Project support

This Agreement is made by and between

JANSSEN-CILAG A/S, a Johnson & Johnson company with its registered address at Bregnerødvej 133 2, DK-3460 Birkerød, Denmark, VAT no.: DK19248615

hereinafter “**Company**”;

and

LYLE LYMFEEKRÆFT OG LEUKÆMI, Banetoften 26, 4700 Næstved, Denmark,
CVR: 31 30 68 33

hereafter referred to as “**Organization**”

Company and Organization are individually referred to as a “**Party**”, collectively referred to as the “**Parties**”.

WHEREAS:

- Company is a research-oriented pharmaceutical company active in the development and marketing of medicinal products
- Organization is a patient organization ”Hvert år får ca. 2.600 danskere enten lymfekræft, leukæmi eller MDS, og tallet er stigende. I dag lever godt 20.000 danskere med hæmatologisk kræft, også kaldet blodkræft. LyLe er en patientforening for mennesker, der er ramt af disse sygdomme – direkte som patienter eller indirekte som pårørende. Vores historie går tilbage til 2007, og i dag er LyLe en veletableret, selvstændig og aktiv patientforening baseret på frivilligt arbejde med egen bestyrelse og økonomi.”
- Organization has asked Company to support one of its projects and Company has agreed to provide support under the terms of this agreement.

THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS:

Article 1: Scope

1. Organization will carry out the Project for which Company will provide support and Organization shall ensure that the contribution is used in a professional and ethical manner consistent with this Agreement and applicable rules, legislation and code of practice. More details on the Project (including the objective, roles and responsibilities of both parties, contact persons, outputs, reporting and timelines) are included in **Annex 1**,
2. Organization will use the support provided by Company exclusively for the purpose of the Project.

Article 2: Support

1. The total amount of support that Company will provide for the Project amounts to **75,000.00 DKK**.
2. Further details on the level and type of support, including payment method and timelines, are included in **Annex 1**.
3. Organization and Company acknowledge and agree that the support shall not obligate Organization to purchase, use, recommend, or arrange for the use of any products of Company.
4. EU and National legislation and codes of practice prohibiting the advertising of prescription-only medicines to the general public, apply. Organization and Company acknowledge and agree that Company shall not request, nor shall Organization undertake, the promotion of a particular prescription-only medicine.
5. Organization represents and warrants that it is a tax-exempt entity under the applicable laws and that it is authorized to accept support in the form of financial contribution or other support from private companies such as Company, and that, to the extent applicable, it has performed the necessary notifications or received the necessary approvals. Organization will also keep Company regularly informed of its direct or indirect relationships with government officials and/or government authorities.
6. If any funds provided by Company to Organization under this Agreement remain upon completion of the Project, such surplus shall be refunded by Organization to Company within forty-five (45) days of completion of the project.

Article 3: Use of name and logo or other proprietary materials

1. Organization will publicly recognize that Company provides support for the Project in the following manner: on their web-site

Article 4: Transparency

1. In order to create appropriate transparency on the support to patient organizations by Company, and in line with the applicable code(s) of practice, Company will make the existence of this agreement and details relating thereto publicly available at Janssen Denmark Website www.janssen.com/denmark and Organization explicitly agrees with such disclosure. More precisely, Company will make the following details publicly available:
 - a) Date that the contract was executed;
 - b) Name of the patient organization;
 - c) Country of the patient organization;
 - d) Web address of the patient organization, if available;
 - e) Description of the nature and the purpose of the contribution;
 - f) Amount as contracted, if financial.

In addition, Company will also make copies of this contract available to interested parties upon their request.

2. Company is entitled to increase the level of details made publicly available to patient organizations either as required by applicable rules and legislation, or upon notice to Organization.
3. This article shall survive any termination of the Agreement.

Article 5: Term and termination

1. This Agreement will take effect on the date when the last of the parties has signed, hereafter the Effective Date, and will remain in effect up until the completion of the Project.
2. Both parties have the right to terminate this Agreement upon 2 months written notice notified by registered mail. The respective rights and obligations of both parties in case of early termination of the Project or this Agreement are included in **Annex 1**.

Article 7: Right of Use

1. Organization hereby grants Company a non-exclusive worldwide and in time unlimited right to use in all possible forms and media all copyrightable documents or products which are created by Organization in the course of performance of this Agreement (hereinafter the “**Work**”), including, without limitation the right to use, adapt, edit, chose a title for the Work, translate, input and/or combine into (conventional, electronic, digital) database, reproduce (regardless of media of reproduction and of number of reproduced copies), publish, make available online (including in intranets and in the internet), sell, lease, give away for free, exhibit, record, film, and broadcast the Work, in its entirety or in part, in all forms of media, whether in printed or recorded form (analogous or digital), and regardless of whether in writing, as sound and/or as image, and regardless of whether for commercial or charitable purpose (“**Right of Use**”). The remuneration of Organization pursuant to this Agreement shall serve as sufficient consideration for granting of the Right of Use.
2. The Right of Use shall survive the termination of this Agreement. Company shall be entitled to assign or to sublicense in part or in full said Right of Use.
3. Organization warrants that in granting the Right of Use, no rights of third parties, including data privacy rights have been infringed and that where necessary, Organization has obtained approval by third parties in order to grant said Right of Use to Company. Organization shall hold Company harmless against third party claims for infringement of copyrights related to the Right of Use granted to Company and shall assist Company in defending against such third party claims.

Article 8: General Provisions

1. General Anti-Corruption Compliance Provision

Neither party shall perform any actions that are prohibited by local and other anti-corruption laws (collectively “**Anti-Corruption Laws**”) that may be applicable to one or both parties to the Agreement. Without limiting the foregoing, neither party shall make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other third party related to the transaction in a manner that would violate Anti-Corruption Laws.

2. Personal Data

Company needs to collect personal information from the Organization, and Company and its affiliates will use such information, in order to manage Company's relationship with the Organization pursuant to this letter agreement. A list of affiliates is at <http://www.investor.jnj.com/sec.cfm> (click on the link to Form 10K, Exhibit 21, under "SEC Filings"). Company may also disclose the Organization's personal information to third-parties service providers, such as technology and marketing service providers, and parties engaged in the organization of events, including hotels and airlines. If the Organization does not provide the personal information requested, Company will not be able to fulfill its obligations to the Organization pursuant to this letter agreement. Based on the Company's legitimate interests, Company may use the Organization's personal information to compile statistical data based on the information in our databases, as well as on surveys, customer feedback questionnaires, and similar communications.

The Organization may contact Company with questions or request to review the personal information Company has collected and/or to request its correction, deletion, blocking, data portability or restriction at: jacdk@its.jnj.com. The Organization may also lodge a complaint with a data protection authority for the Organization's country or region.

The use and disclosure of personal information may involve a transfer to other jurisdictions, including the U.S., which may provide for different data protection rules than in the Organization's country. Appropriate contractual and other measures are in place to protect personal information when it is transferred. The Organization may obtain a copy of these measures by contacting the Company's data protection officer responsible for the Organization's country or region, if applicable, at emeaprivacy@its.jnj.com.

Company will retain the Organization's personal information for as long as needed or permitted in the light of the purpose(s) for which it was obtained, based on: (i) the length of time Company has an ongoing relationship with the Organization; (ii) whether there is a legal obligation to which Company is subject; and (iii) whether retention is advisable in light of the Company's legal position.

3. Governing Law

This Agreement shall be governed by and construed under the laws of Denmark, without reference to the conflict of law rules.

4. Dispute Resolution

In case of any dispute arising out of or in connection with this Agreement, the Parties shall first attempt (in good faith) to reach an amicable settlement. Should such amicable settlement fail, the courts of Denmark shall have exclusive jurisdiction.

5. Electronic Signatures

The Parties explicitly agree to execute this Agreement by way of an electronic signature, and agree this shall constitute a valid and enforceable agreement between the Parties. The present Agreement is made in an electronic pdf-version (using Adobe Sign) which shall be electronically signed by each Party. Each Party hereby acknowledges receipt of the e-signed agreement, electronically signed for approval by both Parties.

For Company:

Mikkel Johansen
Electronically signed by: Mikkel Johansen
Reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Date: Nov 28, 2024 17:06 GMT+1

Market Access & Policy Director

For ORGANIZATION:

Rita Christensen
Electronically signed by: Rita Christensen
Reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Date: Nov 28, 2024 11:48 GMT+1

Chair

Annex 1: Project details

From: Rita Christensen <rita@lyle.dk>
Sent: 6. november 2024 10:05
To: Bordinggaard, Dorthe [JACDK] <DBording@ITS.JNJ.com>
Cc: Zeidler, Anders [JACDK] <AZeidler@ITS.JNJ.com>
Subject: [EXTERNAL] VS: Dybdeinterviews og udbredelse

Kære Dorthe,

Vil du være med til at følge op på patientundersøgelsen om medicinfrie perioder for CLL patienter?

Vi er meget glade for den indsigt, som det kvantitative livskvalitetsstudie har givet os om patienters oplevelse af medicinfrie perioder. Du kan læse udfaldet af undersøgelsen [her](#):

Vi noterer os, at mange er trygge ved overgangen og forbliver trygge, mens de er medicinfrie. Men vi bemærker også, at hver anden bekymrer sig over at skulle ud af behandling, og at hele 63 % forbliver bekymrede under den medicinfrie periode.

Vi ønsker at få en dybere forståelse af folks bekymringer op til medicinfrihed og under forløbet. Dette for at vi kan tale ind i bekymringen og støtte dem, der har behovet med de rette støtteværktøjer.

Derfor søger vi støtte til opfølgende dybdeinterviews med flere af deltagerne i undersøgelsen. 18 af de deltagere, der bekymrer sig, har tilkendegivet, at vi godt må kontakte dem for opfølgning, og det er det, vi nu ønsker at benytte os af.

Vi håber, I vil være med til at støtte projektet. Projektet vil – på baggrund af dybdeinterviewene – udmunde i forskellige initiativer for udbredelse af findings:

- Afrapportering ved (online) møde, hvor I får mulighed for at stille uddybende spørgsmål.
- Rapport, der beskriver patientprofiler og analyserer tendenser, tilsendt til jer.
- Patienthistorie til lyle.dk og vores medlemsblad
- Handout af rapportens findings som print, så I kan dele den med relevante sundhedsfaglige og derigennem skabe dialog. Det kan forhåbentlig være med til at sikre øget fokus på, hvordan patienterne kan blive mere trygge i de medicinfrie perioder.

- Social Media kampagne på vores Facebook side
- Mini-presseindsats henvendt mod Hæmatologisk Tidsskrift for at udbrede kendskabet hos fagligheden

Vedhæftet budget, som vi håber at kunne dele ligeligt mellem deltagende sponsorer, dvs. 91.550 dkk ex moms (faktureret gennem Molecule) eller 114.437,50 dkk inkl. moms (faktureret gennem LyLe). Fakturering kan deles mellem 2024 og 2025.

Jeg håber, I har lyst til at være iblandt de deltagende sponsorer og ser frem til at høre fra jer,

Mange hilsener

Rita

O.

Christensen

Formand

Patientforeningen

for

Lymfekræft,

Leukæmi

og

MDS

Banetoften

26,

4700

Næstved

31 68 26

00

-

formand@lyle.dk -

<https://lyle.dk/>





Patientforeningen for lymfekræft og
leukæmi og MDS
Banetoften 26
4700 Næstved
Rita Christensen

Budget

Jobnr.: 22239
Dato: 5. november 2024
Fra: Maria Alstrup Udsen

Job 22239 - Dybdeinterviews og udbredelse

Her budget for screening og dybdeinterviews med deltagere i LyLes livskvalitetsstudie om medicinfrihed. Interviewene har til formål at afdække, hvilke bekymringer patienter har op mod en medicinfri periode - og hvilke bekymringer, der måske fortsætter, mens de er i den medicin frie periode. Budgettet inkluderer flere mulige måder at udbrede findings på over for patienter, pårørende og sundhedsfaglige, inkl. to kampagner på de sociale medier, der hhv. deler data fra rapporten med fokus på medicinfrihed; og deler indsigter fra dybdeinterviews med fokus på bekymringer ved medicinfrihed og coping heraf.

Opstart og formålsbeskrivelse	18.600
Opstartsmøde for at afstemme ønsker til afdækning, spørgsmål, vinkling mm Scope af opgaven og kort projektbeskrivelse med formål, målgrupper, formater og kanaler	
Screening	27.350
Datasegmentering af mulige patienter til dybdeinterview Kort spørgeramme til patienter via mail eller telefon (afhængigt af, hvad de har opgivet af kontaktdata) Kort telefonisk præinterview af op til 12 patienter med fokus på deres bekymringer ved medicinfrihed og egnethed til dybdeinterview Kortfattede personkarakteristik af op til 12 screenede patienter Projektledeelse og løbende afstemning med LyLe	
Dybdeinterviews	55.300
Segmentering af screenede patienter og udvælgelse af 6 patienter til dybdeinterviews Udvidet spørgeramme Bivirkningstræning og -indrapportering, hvis relevant 6 telefoniske dybdeinterviews Bearbejdning af interviews inkl. transkribering Analyse af findings på tværs af interviews Projektledeelse og løbende afstemning med LyLe	
Rapport	38.100
Opsætning af rapport med kort præsentation af patientprofiler (blinded), unikke karaktertræk og analyse på tværs af profiler og findings Online møde med præsentation af rapport Evt. finjustering af rapport og efterfølgende deling med LyLe og involverede sponsorer Løbende afstemning med LyLe	



Patientforeningen for lymfekræft og
leukæmi og MDS
Banetoften 26
4700 Næstved
Rita Christensen

Budget

Jobnr.: 22239
Dato: 5. november 2024
Fra: Maria Alstrup Udsen

Patienthistorie til LyLe web og medlemsblad	28.700
1 artikel i to versioner til hhv, LyLe.dk og LyLes medlemsblad	
Artiklen indeholder beretninger fra en mandlig og kvindelig patient, der beskriver bekymringer og håndtering	
Fotografering af de to patienter til bladet og evt. Social Media kampagne	
Samtykkeerklæring	
Handout til de sundhedsfaglige	29.300
A4 fold-ud print, der præsenterer patientprofiler og relevante patientoplevelser og -bekymringer ved medicinfrihed	
Ingen omtale af specifikke behandlinger	
Tryk af op til 500 ex, som LyLe og sponsorer kan dele på klinikker og afdelinger	
Artikel til Hæmatologisk Tidsskrift	19.200
Mini-presseindsats over for Hæmatologisk Tidsskrift og den sundhedsfaglige målgruppe for artikel om livskvalitetsstudie evt. suppleret af dybdeinterviews	
Social Media kampagne 1 medicinfrihed	47.500
Kampagne på LyLes Facebook med 3 posts, der deler data fra rapporten med visuelle indtrækkere og info om medicinfrihed.	
Inkl. copy, visuals, målgruppesegmentering, opsætning, performancerapport og annoncebudget sat til 7.000 i alt fordelt på de tre posts.	
Social Media kampagne 2 bekymringer og støtte ved medicinfrihed	58.100
Kampagne på LyLes Facebook med 4 posts, der taler ind i de bekymringer, patienter kan opleve ved medicinfrihed - og hvad de kan gøre.	
Inkl. copy, visuals, målgruppesegmentering, opsætning, performancerapport og annoncebudget sat til 12.000 i alt fordelt over 4 posts.	
I alt ekskl. moms, DKK	322.150
25% Moms af 322.150	80.538
I alt inkl. moms, DKK	402.688

Betalingsbetingelser: Sidste rettidige indbetalingsdato er fakturadato + 14 dage.



Patientforeningen for lymfekræft og
leukæmi og MDS
Banetoften 26
4700 Næstved
Rita Christensen

Budget

Jobnr.: 22239
Dato: 5. november 2024
Fra: Maria Alstrup Udsen

Venlig hilsen

Maria Alstrup Udsen
Molecule Consultancy

Payment method:

Company shall pay the Support within 45 days of being issued an invoice. Payments shall be made by bank transfer and only to a bank account held in the name of the Party on Invoice. Invoices should, as a minimum requirement, contain the following items: (a) full name and address of Party issuing the invoice; (b) where applicable tax number of Party issuing the invoice; (c) full name and address of the Company or its appointed agent; (d) place and date of invoice; (e) brief description of services invoiced with date of service rendered; and (f) where value added tax (VAT) is applicable, invoicing Party's VAT number, statement of net amounts invoiced, VAT rate, amount and gross amounts. Company will inform the Organization in case the invoice needs to be addressed to its appointed agent instead of to Company.

The Support shall be paid to the Organization's intermediary Molecule Consultancy ("Intermediary") acting on behalf and for the account of the Organization in the setting up and facilitation of the Project subject to the Support. The Organization must be mentioned on the invoice from the Intermediary. Company shall not be involved and/or be otherwise responsible in the further/subsequent dealings as between the Organization and the Intermediary.

Invoicing will be performed via the Intermediary:
Molecule Consultancy,
Dampfærgevej 27-29 5. sal,
2100 København Ø, Denmark
[VAT-number: 28515766

Reporting:

Within 1 month from the activity, the organization will write a small report as proof of event. The report should consist of:

- A letter on the organization's own letterhead-paper, signed by them, where they explain how the grant/support was used and confirm that the grant/support (amount) has been used as agreed upon.

And at least one of following:

- Final agenda/Advertisement/ Receipts of costs/ detailed financial accounting for use of the support

Those parts can be combined in the same document, but the content must align with the requirements.











[2154483] Sponsorship - Other

Final Audit Report

2024-11-28

Created:	2024-11-28
By:	J&J ICD system (icdsup@its.jnj.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAGM7-f2cf2NonCdBLWP-ZSkEON-P11ih-

"[2154483] Sponsorship - Other" History

-  Document created by J&J ICD system (icdsup@its.jnj.com)
2024-11-28 - 10:10:08 AM GMT- IP address: 199.65.128.90
-  Document emailed to Mikkel Johansen (mjohan12@its.jnj.com) for signature
2024-11-28 - 10:11:32 AM GMT
-  Document emailed to rita@lyle.dk for signature
2024-11-28 - 10:11:32 AM GMT
-  Email viewed by rita@lyle.dk
2024-11-28 - 10:46:51 AM GMT- IP address: 217.74.146.254
-  Signer rita@lyle.dk entered name at signing as Rita Christensen
2024-11-28 - 10:48:41 AM GMT- IP address: 217.74.146.254
-  Rita Christensen (rita@lyle.dk) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.
2024-11-28 - 10:48:43 AM GMT- IP address: 217.74.146.254
-  Document e-signed by Rita Christensen (rita@lyle.dk)
Signing reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Signature Date: 2024-11-28 - 10:48:43 AM GMT - Time Source: server- IP address: 217.74.146.254
-  Email viewed by Mikkel Johansen (mjohan12@its.jnj.com)
2024-11-28 - 4:05:39 PM GMT- IP address: 165.225.194.186
-  Mikkel Johansen (mjohan12@its.jnj.com) has agreed to the terms of use and to do business electronically with JOHNSON AND JOHNSON SERVICES, INC.
2024-11-28 - 4:06:30 PM GMT- IP address: 165.225.194.186
-  Document e-signed by Mikkel Johansen (mjohan12@its.jnj.com)
Signing reason: I acknowledge that my electronic signature is the legally binding equivalent for my handwritten signature
Signature Date: 2024-11-28 - 4:06:30 PM GMT - Time Source: server- IP address: 165.225.194.186

✔ Agreement completed.

2024-11-28 - 4:06:30 PM GMT